Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion.

Glucagon-like peptide-1 (GLP-1) type obesity drug craze is hot.Demand for Novo Nordisk's Ozempic, Hugo Bee, and Eli Lilly's ...

MERCK snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as US$2 billion. Read ...

Merck & Co. Inc. has turned to Asia for a second time to get into the GLP-1 market, this time to Shanghai-based Hansoh ...

By licensing a drug from Hansoh, Merck signaled that it isn’t prepared to fully challenge its rivals' dominance in the GLP-1 ...

Merck (MRK) closed at $98.34 in the latest trading session, marking a -1.72% move from the prior day. This move was narrower than the S&P 500's daily loss of 2.95%. Meanwhile, the Dow lost 2.59%, and ...

The dynamics of the germ cell tumors market are anticipated to change in the coming years owing to the approval of ...

The dengue viruses primarily circulate in the tropics and subtropics and are transmitted to people by infected mosquitoes.

The Chinese Communist Party intends to add more nuclear arms to its growing arsenal while expanding its global influence and ...

Russia said it has developed a cancer vaccine that will be distributed to Russian patients for free starting in early 2025 — ...

The report urged citizens and healthcare workers not yet vaccinated against COVID-19 or seasonal influenza to do so as soon ...

Merck announced a weight loss drug deal Wednesday with China-based Hansoh worth up to $2 billion for the pill code-named ...